Breaking Barriers: Streamlining Target Prioritization for Swift Scientific Insights

Join this webinar to hear from a satisfied partner who achieved a remarkable 500% increase in insight discovery speed, streamlined research timelines from months to days, and enhanced innovation potential.

In this webinar: 

  • Learn how to use vast biomedical knowledge to build hypotheses with high confidence;
  • Explore how AI can be leveraged for Target Discovery;
  • Master how to perform efficient & robust drug target prioritization for stellar results;
  • See how research time to insight can be slashed from months to just a couple of days.

Register today!

When:
Thursday, February 22th
11 am EST | 4 pm GMT | 5 pm CEST

This webinar is for:

  • Drug Hunters
  • Data Scientists
  • Biologists and medical experts
  • Therapeutic Area heads and translational researchers
  • Current & future users of Ontotext’s Target Discovery

Expected duration:

  • 45 minute

Other Information:

  • This is a live webinar
  • Live Question Answering: Yes
  • Resource After Webinar: Recording and presentation

 

Sign-up for this webinar

About The Speaker

Martina Markova

Martina Markova

Product Manager & Business Analyst

Martina Markova is Ontotext's Product Manager of Target Discovery and Business Analyst in Ontotext’s Life Sciences and Healthcare department. She brings experience from both the clinical and preclinical drug development phases, and has helped top pharma companies, CROs, academia and biotech startups in their journeys to successfully leverage cutting edge digital technologies.

Montdher Hussain

Montdher Hussain

MSc Pathology and Molecular Medicine at Queen's University

Montdher Hussain is a graduate student at Queen's University, Canada in the department of Pathology and Molecular Medicine. His research focuses on elucidating proteins that mediate activity of the receptor tyrosine kinase RET in cancers. To do this, he harness the power of large-scale genetic screens to identify candidates which I then validate through in vitro studies using models of RET hyperactivity.